ImmunityBio, Inc. - Common Stock (NQ:IBRX)

6.210 -0.240 (-3.72%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 26, 2026 Add to My Watchlist

Price and Volume

Volume	36,786,281
Open	6.660
Bid (Size)	6.240 (4,900)
Ask (Size)	6.250 (900)
Prev. Close	6.450
Today's Range	6.160 - 6.750
52wk Range	1.830 - 8.280
Shares Outstanding	391,156,513
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

IBRX Stock Gains Pre-Market After A Volatile Trading Session Following Phase 2 Glioblastoma Trial Update: Retail Backs ImmunityBio’s Cancer Research ↗

Today 7:06 EST

Patrick Soon Shiong, ImmunityBio’s founder, took to X on Saturday to clarify what the update signified.

Via Stocktwits

Nasdaq, S&P 500 Futures Open The Week On Edge As Earnings, Tariffs, Fed Decision Loom: Why META, NVDA, RVMD, USAR Are On Traders' Radar Today ↗

Today 3:22 EST

Via Stocktwits

Performance

YTD	+207.4%	+207.4%
1 Month	+190.9%	+190.9%
3 Month	+133.5%	+133.5%
6 Month	+134.3%	+134.3%
1 Year	+98.4%	+98.4%

More News

$5 Stocks: NDRA, IBRX, MOVE, RVLY Drawing Attention Watch Now!

January 25, 2026

Via AB Newswire

Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month ↗

January 23, 2026

Via The Motley Fool

IBRX Stock Extends Rally On FDA Feedback For ANKTIVA Bladder Cancer Filing ↗

January 20, 2026

Via Stocktwits

Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today ↗

January 16, 2026

Via Stocktwits

IBRX Stock Continues Rally — What’s Driving The Optimism Today? ↗

January 15, 2026

Via Stocktwits

IBRX Stock Sees Volatile Session – ImmunityBio’s Update In Phase 2 Glioblastoma Trial Sparks Buzz ↗

January 23, 2026

Via Stocktwits

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

January 23, 2026

From ImmunityBio, Inc.

Via Business Wire

Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses ↗

January 21, 2026

Via The Motley Fool

Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer ↗

January 20, 2026

Via The Motley Fool

Which stocks are most active on Tuesday? ↗

January 20, 2026

Via Chartmill

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

January 20, 2026

From ImmunityBio, Inc.

Via Business Wire

Nasdaq, S&P 500 Futures Slide As Trump Ramps Up Greenland Threats: Why NFLX, CRML, TSLA, VERO, SRXH Are On Traders' Radar Today ↗

January 20, 2026

Via Stocktwits

Why Is ImmunityBio Stock Back In Retail Spotlight Today? ↗

January 19, 2026

Via Stocktwits

Nasdaq, S&P 500 Futures Slide On Greenland Tensions: Why NVDA, MU, IBRX, CRML And VERO Are On Traders’ Radar Today ↗

January 19, 2026

Via Stocktwits

Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year ↗

January 16, 2026

Via The Motley Fool

Which stocks are experiencing notable movement on Friday? ↗

January 16, 2026

Via Chartmill

Why ImmunityBio Stock Is Skyrocketing Again Today ↗

January 16, 2026

Via The Motley Fool

Curious about the most active stocks on Friday? ↗

January 16, 2026

Via Chartmill

Keep an eye on the top gainers and losers in Friday's session. ↗

January 16, 2026

Via Chartmill

Friday's session: gap up and gap down stocks ↗

January 16, 2026

Via Chartmill

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

January 16, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

January 16, 2026

From ImmunityBio, Inc.

Via Business Wire

Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700% ↗

January 15, 2026

Via The Motley Fool

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?

Yes, ImmunityBio, Inc. - Common Stock is publicly traded.

What exchange does ImmunityBio, Inc. - Common Stock trade on?

ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ImmunityBio, Inc. - Common Stock?

The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market

What is the current price of ImmunityBio, Inc. - Common Stock?

The current price of ImmunityBio, Inc. - Common Stock is 6.210

When was ImmunityBio, Inc. - Common Stock last traded?

The last trade of ImmunityBio, Inc. - Common Stock was at 01/26/26 04:00 PM ET

What is the market capitalization of ImmunityBio, Inc. - Common Stock?

The market capitalization of ImmunityBio, Inc. - Common Stock is 2.43B

How many shares of ImmunityBio, Inc. - Common Stock are outstanding?

ImmunityBio, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.